Medicover GmbH
- Address
- lock Available on a paid plan
Eye Diseases
At Medicover GmbH clinicians are exploring ocular manifestations of systemic autoimmune disorders, aiming to improve detection and management of eye involvement.
- Assessment of retinal inflammation in systemic lupus erythematosus
- Evaluation of visual acuity outcomes in patients receiving biologic therapy
- Development of screening protocols for dry eye in Sjögren’s disease
The program supports interdisciplinary collaboration between ophthalmology and rheumatology to enhance patient care.
Hormonal Diseases
Researchers are conducting long‑term safety studies of octreotide depot for individuals with acromegaly, focusing on hormone control and quality of life.
- Monitoring IGF‑1 levels during treatment
- Evaluating adverse event profiles over extended periods
- Comparing patient‑reported outcomes with standard therapy
Findings will guide dosing strategies and inform clinical guidelines for endocrine disorders.
Immune System Diseases
A broad portfolio of trials investigates novel agents such as dapirolizumab pegol and obexelimab to reduce disease activity in systemic lupus erythematosus and related conditions.
- Safety and tolerability of emerging biologics
- Impact on disease activity scores (SRI‑4, ESSDAI)
- Combination with standard‑of‑care medications
- Relapse prevention in giant cell arteritis
The site’s work aims to expand therapeutic options for patients with complex autoimmune diseases.
Musculoskeletal Diseases
Ongoing studies assess the effectiveness of sonelokimab and tulisokibart in improving joint function for psoriatic arthritis, axial spondyloarthritis, and rheumatoid arthritis.
- ACR50 and ASAS40 response rates
- Radiographic progression monitoring
- Patient‑reported pain and stiffness outcomes
- Comparative analysis with existing biologics
Results are expected to clarify optimal treatment pathways for inflammatory joint diseases.
Nutritional and Metabolic Diseases
The master protocol evaluates orforglipron for weight reduction and glycemic control in participants with obesity, overweight, and type 2 diabetes.
- Body‑weight loss efficacy in non‑diabetic cohort
- Improvement of HbA1c levels in diabetic cohort
- Safety monitoring of metabolic parameters
- Assessment of cardiovascular risk markers
This research could add a new oral therapy option for managing metabolic health.
Skin and Connective Tissue Diseases
Trials focus on biologic agents such as zasocitinib and BIIB059 to target skin involvement and systemic manifestations of psoriasis and lupus.
- Reduction of skin lesion severity scores
- Effects on systemic disease activity indices
- Long‑term safety in diverse patient populations
- Quality‑of‑life improvements measured by validated questionnaires
The outcomes will support personalized treatment strategies for cutaneous and connective tissue disorders.
Stomatognathic Diseases
Investigations address oral dryness and salivary gland dysfunction in primary Sjögren’s disease, aiming to enhance diagnostic tools and therapeutic approaches.
- Validation of salivary flow measurement techniques
- Evaluation of novel systemic agents on oral symptoms
- Patient‑centered outcome measures for oral health
Collaboration with dental specialists ensures comprehensive management of mouth‑related complications.
Immune System Processes
Research programs explore the underlying immune system processes that drive autoimmunity, using biomarkers to predict response to targeted therapies.
- Cytokine profiling in trial participants
- Genetic and epigenetic marker analysis
- Correlation of immune signatures with clinical outcomes
- Development of predictive algorithms for treatment success
Insights gained will refine patient selection and accelerate drug development across multiple disease areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 10 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1MoonLake Immunotherapeutics AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medicover GmbH
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Emtricitabine | 1 | Unknown | 2023-05-17 | 2023-05-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.